Literature DB >> 15115874

Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

A Baldi1, D Santini, F Vasaturo, M Santini, G Vicidomini, M Pia Di Marino, V Esposito, A M Groeger, G Liuzzi, B Vincenzi, G Tonini, M Piccoli, F Baldi, S Scarpa.   

Abstract

BACKGROUND: A study was undertaken to analyse the potential prognostic value of the immunohistochemical expression of cyclooxygenase-2 (COX-2) and p27 in 29 malignant mesotheliomas already screened for the expression of p21 and p53.
METHODS: Immunohistochemistry was used to determine the expression of COX-2 and p27. The correlation with survival of these factors and of p21 and p53 expression was assessed by univariate and multivariate analyses.
RESULTS: A positive statistically significant correlation was found between p27 and p21 expression (p<0.0001), but there was a negative correlation between COX-2 expression and both p27 (p = 0.001) and p21 (p<0.0001). No statistically significant correlation was recorded between p53 and all the other immunohistochemical parameters. Univariate analysis showed that overall survival was strongly influenced by p21, p27, and COX-2 expression, but multivariate Cox regression analysis showed that the only immunohistochemical parameter to influence overall survival of patients with mesothelioma was COX-2.
CONCLUSIONS: These findings suggest that COX-2 expression may be a useful prognostic parameter for mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115874      PMCID: PMC1746992          DOI: 10.1136/thx.2003.008912

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  29 in total

1.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Authors:  V W Rusch; E S Venkatraman
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

2.  Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1.

Authors:  Gunther Zahner; Gunter Wolf; Murwan Ayoub; Rudiger Reinking; Ulf Panzer; Stuart J Shankland; Rolf A K Stahl
Journal:  J Biol Chem       Date:  2001-12-26       Impact factor: 5.157

Review 3.  Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.

Authors:  S Tsuji; M Tsujii; S Kawano; M Hori
Journal:  J Exp Clin Cancer Res       Date:  2001-03

4.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

Authors:  T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

5.  p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.

Authors:  R Isik; M Metintas; A R Gibbs; S Metintas; B Jasani; U Oner; E Harmanci; S Demircan; S Işiksoy
Journal:  Respir Med       Date:  2001-07       Impact factor: 3.415

6.  p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma.

Authors:  M Bongiovanni; P Cassoni; P De Giuli; L Viberti; S Cappia; C Ivaldi; L Chiusa; G Bussolati
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

7.  p27 immunostaining is related to prognosis in malignant mesothelioma.

Authors:  T W Beer; P Shepherd; N C Pullinger
Journal:  Histopathology       Date:  2001-06       Impact factor: 5.087

8.  Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.

Authors:  A Marrogi; H I Pass; M Khan; L J Metheny-Barlow; C C Harris; B I Gerwin
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

9.  Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.

Authors:  A Baldi; A M Groeger; V Esposito; R Cassandro; G Tonini; T Battista; M P Di Marino; B Vincenzi; M Santini; A Angelini; R Rossiello; F Baldi; M G Paggi
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

10.  COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.

Authors:  S Grösch; I Tegeder; E Niederberger; L Bräutigam; G Geisslinger
Journal:  FASEB J       Date:  2001-10-15       Impact factor: 5.191

View more
  10 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Authors:  Daniela Stoppoloni; Claudia Canino; Irene Cardillo; Alessandra Verdina; Alfonso Baldi; Ada Sacchi; Rossella Galati
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

Review 3.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

5.  Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma.

Authors:  Alfonso Baldi; Maria Teresa Piccolo; Maria Rosaria Boccellino; Aldo Donizetti; Irene Cardillo; Raffaele La Porta; Lucio Quagliuolo; Enrico P Spugnini; Francesca Cordero; Gennaro Citro; Massimo Menegozzo; Raffaele A Calogero; Stefania Crispi
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

6.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

7.  The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Authors:  Lily Oguh-Olayinka; Vijay Agarwal; Dulani Ranatunge; Anne Campbell; Stefan Laufer; Lynn Cawkwell; Michael J Lind
Journal:  Pathol Oncol Res       Date:  2019-04-02       Impact factor: 3.201

Review 8.  Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Authors:  Melanie Vogl; Anna Rosenmayr; Tomas Bohanes; Axel Scheed; Milos Brndiar; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

9.  Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.

Authors:  Alessandra Verdina; Irene Cardillo; Angela Nebbioso; Rossella Galati; Simona Menegozzo; Lucia Altucci; Ada Sacchi; Alfonso Baldi
Journal:  J Transl Med       Date:  2008-05-22       Impact factor: 5.531

10.  Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Authors:  David W Greening; Hong Ji; Maoshan Chen; Bruce W S Robinson; Ian M Dick; Jenette Creaney; Richard J Simpson
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.